JPRN-UMIN000004764已完成2 期
Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancer - Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) with severe allergy to Trastuzumab and TS-1 and 5-FU based drug 2) with history of severe allergy 3) pregnant or nursing women 4) with wide liver metastasis or lymphangitic pulmonary metastasis with respiratory distress 5) with active double cancer 6) with cerebral metastasis 7) with metastatic lesions observed only in their bones 8) with uncontrollable heart failure, angina pectoris, congestive cardiac failure, history of myocardial infarction, abnormal cardiac rhythm which need to treat 9) uncontrolled diabetes 10) with pulmonary fibrosis or pneumonitis 11) with dyspnea at rest 12) with uncontrolled pleural effusion, peritoneal effusion, pericardial effusion 13) possible infection associated with clinical symptoms such as fever 14) doctor's decision not to be registered to this study
研究者
相似试验
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45
已完成
2 期
A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast CancerBreast cancerJPRN-UMIN000001408Gunma Breast Clinical Conference Study Group(GBCCSG)30
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
招募中
2 期
Phase II single-arm study of Trastuzumab combination with Cisplatin and Gemcitabine as first-line therapy in the HER-2 positive Advanced CholangioCArcinomaAdvanced biliary tract cancersHER-2 positiveFirst-line therapyGallbladder CancerBiliary Tract CancersOncogene Protein HER-2TrastuzumabCisplatinGemcitabineCancer Chemotherapy AgentCombined Antineoplastic AgentsCholangiocarcinomaTCTR20220328005Khon Kaen University33